Origin created the name Seglentis® for ESTEVE, an innovative first-in-class product comprised of a co-crystal form of celecoxib (an anti-inflammatory) and tramadol (an analgesic) for the management of acute pain in adults.
Seglentis® is a new chemical entity, there was no regulatory precedent for the evaluation and classification of this type of API (Active Pharmaceutical Ingredient) co-crystal prior to its presentation to the FDA by ESTEVE.
More than just a simple (traditional) fixed dose combination product, the co-crystal structure leverages the efficacy properties of both compounds while lowering the component dosages and associated adverse effects and helps to address opioid usage concerns by providing pain relief at much lower doses and better tolerability.
The name Seglentis® is confident and re-assuring, with positive messaging derived from
‘secure’ and ‘lenity’; it re-enforces the ‘synergistic analgesic effect’ positioning and suggests well-being (reduced side effects) and better pain relief/management.
Seglentis® will be commercialized in the United States by KOWA Pharmaceuticals America, Inc.